Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 414 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2014', provides an overview of the Diffuse Large B-Cell Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diffuse Large B-Cell Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview 11
Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis 12
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 13
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 18
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Diffuse Large B-Cell Lymphoma - Products under Development by Companies 22
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 27
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 28
Bristol-Myers Squibb Company 28
Boehringer Ingelheim GmbH 29
F. Hoffmann-La Roche Ltd. 30
Amgen Inc. 31
Sanofi 32
AstraZeneca PLC 33
GlaxoSmithKline plc 34
Seattle Genetics, Inc. 35
Genentech, Inc. 36
MedImmune, LLC 37
Gilead Sciences, Inc. 38
Merck & Co., Inc. 39
Infinity Pharmaceuticals, Inc. 40
Celltrion, Inc. 41
Millennium Pharmaceuticals, Inc. 42
Novartis AG 43
Astellas Pharma Inc. 44
ImmunoGen, Inc. 45
Ono Pharmaceutical Co., Ltd. 46
Taiho Pharmaceutical Co., Ltd. 47
Sandoz Inc. 48
Celgene Corporation 49
Onyx Pharmaceuticals, Inc. 50
Bayer AG 51
Incyte Corporation 52
Immunomedics, Inc. 53
Idera Pharmaceuticals, Inc. 54
Curis, Inc. 55
Portola Pharmaceuticals, Inc. 56
Pharmacyclics, Inc. 57
Senesco Technologies, Inc. 58
Spectrum Pharmaceuticals, Inc. 59
Affimed Therapeutics AG 60
Memgen, LLC. 61
Priaxon AG 62
Respiratorius AB 63
Constellation Pharmaceuticals, Inc. 64
ProNAi Therapeutics, Inc. 65
Cell>Point 66
Aprogen, Inc. 67
Selvita S.A 68
Karyopharm Therapeutics, Inc. 69
Kite Pharma, Inc. 70
Arrien Pharmaceuticals, LLC 71
AbbVie Inc. 72
Mirati Therapeutics Inc. 73
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 74
Assessment by Monotherapy Products 74
Assessment by Target 75
Assessment by Mechanism of Action 79
Assessment by Route of Administration 84
Assessment by Molecule Type 86
Drug Profiles 88
obinutuzumab - Drug Profile 88
ibrutinib - Drug Profile 90
everolimus - Drug Profile 95
ibritumomab tiuxetan - Drug Profile 99
rituximab biosimilar - Drug Profile 101
rituximab biosimilar - Drug Profile 102
bendamustine hydrochloride - Drug Profile 103
MK-2206 - Drug Profile 105
alisertib - Drug Profile 108
coltuximab ravtansine - Drug Profile 112
blinatumomab - Drug Profile 114
brentuximab vedotin - Drug Profile 117
mocetinostat - Drug Profile 122
panobinostat - Drug Profile 125
bortezomib - Drug Profile 131
ruxolitinib phosphate - Drug Profile 136
idelalisib - Drug Profile 140
ISF-35 - Drug Profile 142
MEDI-551 - Drug Profile 144
epratuzumab - Drug Profile 146
tisagenlecleucel-T - Drug Profile 151
vorinostat - Drug Profile 153
buparlisib hydrochloride - Drug Profile 156
lenalidomide - Drug Profile 160
luminespib - Drug Profile 163
nivolumab - Drug Profile 166
PNT-2258 - Drug Profile 170
pinatuzumab vedotin - Drug Profile 172
polatuzumab vedotin - Drug Profile 174
GS-9973 - Drug Profile 176
valproate sodium - Drug Profile 177
moxetumomab pasudotox - Drug Profile 178
ibrutinib - Drug Profile 180
sotrastaurin acetate - Drug Profile 185
BVX-20 - Drug Profile 187
carfilzomib - Drug Profile 188
SNS-01T - Drug Profile 191
AZD-9150 - Drug Profile 192
PRT-2070 - Drug Profile 193
Cell Therapy to Inhibit CD19 for Oncology - Drug Profile 194
KTE-C19 CAR - Drug Profile 195
pevonedistat hydrochloride - Drug Profile 196
ulocuplumab - Drug Profile 198
AFM-11 - Drug Profile 199
copanlisib - Drug Profile 200
romidepsin - Drug Profile 203
CC-223 - Drug Profile 205
CC-292 - Drug Profile 206
duvelisib - Drug Profile 208
BI-836826 - Drug Profile 210
IMGN-529 - Drug Profile 211
venetoclax - Drug Profile 212
CC-122 - Drug Profile 215
selinexor - Drug Profile 217
Drug to Inhibit Bcl-6 for Diffuse Large B-Cell Lymphoma - Drug Profile 219
AZD-3965 - Drug Profile 220
CPI-0610 - Drug Profile 221
ACP-196 - Drug Profile 222
GSK-2816126 - Drug Profile 223
IMO-8400 - Drug Profile 224
rituximab biosimilar - Drug Profile 226
CUDC-907 - Drug Profile 228
rituximab biosimilar - Drug Profile 230
Platinum-Ethylenedicysteine-Glucosamine - Drug Profile 231
187Re-EC-G - Drug Profile 232
ND-2110 - Drug Profile 233
ND-2158 - Drug Profile 235
BLyS-gel - Drug Profile 237
PRT-060318 - Drug Profile 238
pecazine - Drug Profile 239
SEL24-B489 - Drug Profile 240
TEN-010 - Drug Profile 241
rituximab biosimilar - Drug Profile 242
79-6 - Drug Profile 243
rituximab biosimilar - Drug Profile 244
rituximab biosimilar - Drug Profile 245
ARN-3236 - Drug Profile 246
NBD Peptide - Drug Profile 247
TAS-5567 - Drug Profile 249
SH-7129 - Drug Profile 250
IT-901 - Drug Profile 252
Small Molecule to Inhibit BTK for Cancer - Drug Profile 253
Small Molecules to Inhibit MALT-1 for Diffuse Large B-Cell Lymphoma - Drug Profile 254
PXN-490 - Drug Profile 255
Small Molecules to Inhibit NF-kappa B for Diffuse Large B-Cell Lymphoma - Drug Profile 256
Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates 257
Diffuse Large B-Cell Lymphoma - Dormant Projects 393
Diffuse Large B-Cell Lymphoma - Discontinued Products 394
Diffuse Large B-Cell Lymphoma - Product Development Milestones 395
Featured News & Press Releases 395
Appendix 407
Methodology 407
Coverage 407
Secondary Research 407
Primary Research 407
Expert Panel Validation 407
Contact Us 408
Disclaimer 408

List of Tables
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2014 17
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 20
Number of Products under Development by Companies, H2 2014 (Contd..1) 21
Number of Products under Development by Companies, H2 2014 (Contd..2) 22
Number of Products under Development by Companies, H2 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Late Stage Development, H2 2014 25
Comparative Analysis by Clinical Stage Development, H2 2014 26
Comparative Analysis by Early Stage Development, H2 2014 27
Products under Development by Companies, H2 2014 28
Products under Development by Companies, H2 2014 (Contd..1) 29
Products under Development by Companies, H2 2014 (Contd..2) 30
Products under Development by Companies, H2 2014 (Contd..3) 31
Products under Development by Companies, H2 2014 (Contd..4) 32
Products under Investigation by Universities/Institutes, H2 2014 33
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 34
Diffuse Large B-Cell Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 35
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 36
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H2 2014 37
Diffuse Large B-Cell Lymphoma - Pipeline by Sanofi, H2 2014 38
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca PLC, H2 2014 39
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline plc, H2 2014 40
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2014 41
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H2 2014 42
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2014 43
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2014 44
Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2014 45
Diffuse Large B-Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 46
Diffuse Large B-Cell Lymphoma - Pipeline by Celltrion, Inc., H2 2014 47
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 48
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H2 2014 49
Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2014 50
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2014 51
Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 52
Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 53
Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz Inc., H2 2014 54
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H2 2014 55
Diffuse Large B-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 56
Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H2 2014 57
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H2 2014 58
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2014 59
Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 60
Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H2 2014 61
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 62
Diffuse Large B-Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2014 63
Diffuse Large B-Cell Lymphoma - Pipeline by Senesco Technologies, Inc., H2 2014 64
Diffuse Large B-Cell Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 65
Diffuse Large B-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2014 66
Diffuse Large B-Cell Lymphoma - Pipeline by Memgen, LLC., H2 2014 67
Diffuse Large B-Cell Lymphoma - Pipeline by Priaxon AG, H2 2014 68
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H2 2014 69
Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014 70
Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2014 71
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, H2 2014 72
Diffuse Large B-Cell Lymphoma - Pipeline by Aprogen, Inc., H2 2014 73
Diffuse Large B-Cell Lymphoma - Pipeline by Selvita S.A, H2 2014 74
Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 75
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H2 2014 76
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 77
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H2 2014 78
Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2014 79
Assessment by Monotherapy Products, H2 2014 80
Number of Products by Stage and Target, H2 2014 83
Number of Products by Stage and Mechanism of Action, H2 2014 87
Number of Products by Stage and Route of Administration, H2 2014 91
Number of Products by Stage and Molecule Type, H2 2014 93
Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 263
Diffuse Large B-Cell Lymphoma - Dormant Projects, H2 2014 399
Diffuse Large B-Cell Lymphoma - Discontinued Products, H2 2014 400